Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
RESEARCH TOOLSreports
Holding KPTI?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.25Last Year’s EPS
-$0.36Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 05, 2024
|% Change Since: -31.94%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements and opportunities in Karyopharm's clinical trials and market potential, alongside successful cost management and revenue growth. However, the company faces challenges with increased discounts affecting net revenue and a decrease in cash reserves.Company Guidance
During Karyopharm Therapeutics' Q3 2024 earnings call, the company provided optimistic guidance, indicating they are on track to meet or exceed their annual revenue projections. The company reported total revenue of $38.8 million for the quarter, up from $36 million in Q3 2023, with U.S. XPOVIO net product revenue contributing $29.5 million. They highlighted strong performance with a 5% increase in XPOVIO revenues from the previous quarter, attributed to double-digit demand growth. Karyopharm also improved its full-year revenue guidance, with expectations of U.S. XPOVIO net product revenue ranging from $110 million to $115 million, up from the previous range of $105 million to $120 million. The company's ongoing cost-saving initiatives have positively impacted expenses, resulting in a 3% year-over-year decrease. Additionally, Karyopharm remains focused on advancing its Phase III clinical trials, projecting significant market opportunities for SELINEXOR in treating myelofibrosis and endometrial cancer, each potentially generating approximately $1 billion in annual U.S. peak revenues.Regulatory Update on Phase III SENTRY Trial
Karyopharm announced a favorable regulatory update by changing the co-primary endpoint of the SENTRY trial in myelofibrosis to absolute TSS, increasing confidence in the trial's success.
Revenue Growth and Market Potential
Karyopharm reported its third consecutive quarter of net product revenue growth in the U.S., with XPOVIO net product revenue reaching $29.5 million, a 5% increase from the previous quarter.
Significant Market Opportunities
Karyopharm sees potential $1 billion annual U.S. peak revenue opportunities in both myelofibrosis and endometrial cancer, with established commercial infrastructure and strong overlap with existing treatments.
Global Expansion
XPOVIO received reimbursement approvals in Italy and France, expanding its global footprint and increasing its presence in the multiple myeloma market.
Cost Management and Financial Health
Karyopharm reduced SG&A expenses by 10% year-over-year and expects its cash and investments to fund operations into Q1 2026.
---
KPTI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KPTI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $0.93 | $0.84 | -9.68% |
| Aug 06, 2024 | $0.87 | $0.84 | -3.45% |
| May 08, 2024 | $1.10 | $1.02 | -7.27% |
| Feb 29, 2024 | $1.33 | $1.16 | -12.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Karyopharm Therapeutics (KPTI) report earnings?
Karyopharm Therapeutics (KPTI) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Karyopharm Therapeutics (KPTI) earnings time?
Karyopharm Therapeutics (KPTI) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KPTI EPS forecast?
KPTI EPS forecast for the fiscal quarter 2024 (Q4) is -$0.25.
---